SWOG S1513

Primary Category:

Treatment Protocols

Disease Category:

Gastrointestinal, Pancreatic, Pancreatic Metastatic

Status:

Closed

Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

NCT#02890355

S1513 is permanently closed to accrual effective immediately. 12/13/17. At a planned interim analysis, our Data and Safety Monitoring Committee recommended that S1513 be closed permanently based on the results. These results will be shared, and further instructions given in a forthcoming letter to patients and investigators. Patients currently receiving ABT-888 (Veliparib) must discontinue the experimental treatment but may continue on FOLFIRI alone. Patients on both arms should continue study follow-up.